Thrombolytic therapy for patients with acute ischemic stroke: systematic review and network meta-analysis of randomized trials.

ABSTRACT:

Objective

To systematically compare the benefits and risks of all thrombolytic agents (tenecteplase, reteplase, and alteplase) at different doses for thrombolytic therapy in patients with acute ischemic stroke (AIS).

Background

Alteplase is the cornerstone treatment for AIS, but alternative thrombolytic agents are needed. The efficacy and safety of tenecteplase and reteplase, compared to alteplase, remain unclear, as does the optimal dosing for these treatments.

Method

A systematic search was conducted in PubMed, Web of Science, SCOPUS, and the Cochrane Central Register of Controlled Trials (CENTRAL) for relevant English-language studies up to July 5, 2024. Randomized controlled trials (RCTs) comparing standard-dose alteplase with varying doses of tenecteplase or rete

SUBMITTER: Sun LC 

PROVIDER: S-EPMC11746078 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature